Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets

Author's Avatar
May 04, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a collaboration with the German Cancer Research Center (DKFZ), to develop and discover Bicycle® radio conjugates (BRCs) for a range of oncology targets.